Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-15T06:37:25.541Z Has data issue: false hasContentIssue false
  • English
  • Français

Transparency in practice: Evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015

Published online by Cambridge University Press:  08 January 2018

Piotr Ozierański ,
Olga Löblová ,
Natalia Nicholls ,
Marcell Csanádi ,
Zoltán Kaló ,
Martin McKee  and
Lawrence King
Piotr Ozierański*
Affiliation:
Department of Social and Policy Sciences, University of Bath, Bath, UK
Olga Löblová
Affiliation:
Department of Sociology, University of Cambridge, Cambridge, UK
Natalia Nicholls
Affiliation:
Department of Social and Policy Sciences, University of Bath, Bath, UK
Marcell Csanádi
Affiliation:
Doctoral School of Pharmacological and Pharmaceutical Sciences, University of Pecs, Hungary Syreon Research Institute, Hungary
Zoltán Kaló
Affiliation:
Institute of Economics, Eötvös Loránd University, Hungary Syreon Research Institute, Hungary
Martin McKee
Affiliation:
London School of Hygiene and Tropical Medicine, London, UK
Lawrence King
Affiliation:
Department of Economics, University of Massachusetts, Amherst, MA, USA
*
*Correspondence to: Piotr Ozierański, Lecturer, Department of Social and Policy Sciences, University of Bath, Claverton Down, Bath, BA2 7AY, UK. Email: p.ozieranski@bath.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Transparency is recognised to be a key underpinning of the work of health technology assessment (HTA) agencies, yet it has only recently become a subject of systematic inquiry. We contribute to this research field by considering the Polish Agency for Health Technology Assessment (AHTAPol). We situate the AHTAPol in a broader context by comparing it with the National Institute for Health and Care Excellence (NICE) in England. To this end, we analyse all 332 assessment reports, called verification analyses, that the AHTAPol issued from 2012 to 2015, and a stratified sample of 22 Evidence Review Group reports published by NICE in the same period. Overall, by increasingly presenting its key conclusions in assessment reports, the AHTAPol has reached the transparency standards set out by NICE in transparency of HTA outputs. The AHTAPol is more transparent than NICE in certain aspects of the HTA process, such as providing rationales for redacting assessment reports and providing summaries of expert opinions. Nevertheless, it is less transparent in other areas of the HTA process, such as including information on expert conflicts of interest. Our findings have important implications for understanding HTA in Poland and more broadly. We use them to formulate recommendations for policymakers.

Type
Articles
Information
Health Economics, Policy and Law , Volume 14 , Special Issue 2: SPECIAL ISSUE: Frontiers of Health Policy Research , April 2019 , pp. 182 - 204
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bendor, J., Glazer, A. and Hammond, T. (2001), ‘Theories of delegation’, Annual Review of Political Science, 4(1): 235–269.Google Scholar
Bochenek, T., Kocot, E., Rodzinka, M., Godman, B., Maciejewska, K., Kamal, S. and Pilc, A. (2016), ‘The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland’, Expert Review of Pharmacoeconomics & Outcomes Research, 17: 385–400.Google Scholar
del Llano-Señarís, J. E. (2015), ‘What Health Technology Assessment System Do we Really Need? A Critical Review of the Current Situation of Health Technology Assessment in Five European Countries’, in J. E. Llano-Señarís and C. Campillo-Artero (eds), Health Technology Assessment and Health Policy Today: A Multifaceted View of their Unstable Crossroads, e-book: Springer International Publishing, 37–50.Google Scholar
Drummond, M. F., Schwartz, J. S., Jönsson, B., Luce, B. R., Neumann, P. J., Siebert, U. and Sullivan, S. D. (2008), ‘Key principles for the improved conduct of health technology assessments for resource allocation decisions’, International Journal of Technology Assessment in Health Care, 24(3): 244–258.Google Scholar
European Union network for Health Technology Assessment (2017), ‘Mission, vision & values’. EUnetHTA, http://www.eunethta.eu/about-us/mission-vision-values [15 January 2017].Google Scholar
Franken, M., Le Polain, M., Cleemput, I. and Koopmanschap, M. (2012), ‘Similarities and differences between five European drug reimbursement systems’, International Journal of Technology Assessment in Health Care, 28(4): 349–357.Google Scholar
Gulácsi, L., Rotar, A. M., Niewada, M., Löblová, O., Rencz, F., Petrova, G., Boncz, I. and Klazinga, N. S. (2014), ‘Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria’, European Journal of Health Economics, 15(Suppl. 1): S13–S25.Google Scholar
Hailey, D. (2003), ‘Toward transparency in health technology assessment: a checklist for HTA reports’, International Journal of Technology Assessment in Health Care, 19(1): 1–7.Google Scholar
INFARMA and IGFP (2014), ‘Letter to the AHTAPol President’, Warszawa’, http://www.farmacja-polska.org.pl/cms/uploads/dokumenty/C25314081411530.pdf [6 December 2017].Google Scholar
Inotai, A., Pékli, M., Jóna, G., Nagy, O., Remák, E. and Kaló, Z. (2012), ‘Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology’, BMC Health Services Research, 12(1): 332, https://doi.org/10.1186/1472-6963-12-332.Google Scholar
Jakubiak, L. (2014), ‘Zaczernianie danych w analizach – co i jak ukryć – zdania są podzielone’. Rynek Aptek, 17th October, http://www.rynekaptek.pl/marketing-i-zarzadzanie/zaczernianie-danych-w-analizach-co-i-jak-ukryc-zdania-sa-podzielone,6098.html [6 December 2017].Google Scholar
Kaltenthaler, E., Papaioannou, D., Boland, A. and Dickson, R. (2011), ‘The National Institute for Health and Clinical Excellence single technology appraisal process: lessons from the first 4 years’, Value in Health, 14(8): 1158–1165.Google Scholar
Kawalec, P. and Malinowski, K. P. (2016), ‘Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012–2014, a retrospective analysis’, Health Policy, 120(11): 1240–1248.Google Scholar
Kawalec, P., Sagan, A., Stawowczyk, E., Kowalska-Bobko, I. and Mokrzycka, A. (2016), ‘Implementation of the 2011 Reimbursement Act in Poland: desired and undesired effects of the changes in reimbursement policy’, Health Policy, 120(4): 356–361.Google Scholar
Kolasa, K., Dziomdziora, M. and Fajutrao, L. (2011a), ‘What aspects of the health technology assessment process recommended by International Health Technology Assessment agencies received the most attention in Poland in 2008?’, International Journal of Technology Assessment in Health Care, 27(1): 84–94.Google Scholar
Kolasa, K., Schubert, S., Manca, A. and Hermanowski, T. (2011b), ‘A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland’, Health Policy, 102(2–3): 145–151.Google Scholar
Kolasa, K., Kalo, Z., Zah, V. and Dolezal, T. (2012), ‘Role of Health Technology Assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries’, Expert Review of Pharmacoeconomics and Outcomes Research, 12(3): 283–287.Google Scholar
Landwehr, C. and Böhm, K. (2014), ‘Strategic institutional design: two case studies of non-majoritarian agencies in health care priority-setting.’, Government and Opposition, 51(4): 632–660.Google Scholar
Law on Health Care Services Funded from Public Sources (2004), ‘Act of 27th August 2004 on Health Care Services Funded from Public Sources ‘(Ustawa z dnia 27 sierpnia 2004 r. o świadczeniach opieki zdrowotnej finansowanych ze środków publicznych)’.Google Scholar
Law on Protection of Personal Information (1997), ‘Act of 29th August 1997 on Protection of personal information (Ustawa z dnia 29 sierpnia 1997 r. o ochronie danych osobowych)’.Google Scholar
Law on Unfair Competition (1993), ‘Act of 16th of April 1993 on Unfair Competition (Ustawa z dn. 16 kwietnia 1993 r o zwalczaniu nieuczciwej konkurencji)’.Google Scholar
Llano-Señarís, J. E. (2015), ‘What Health Technology Assessment System Do we Really Need? A Critical Review of the Current Situation of Health Technology Assessment in Five European Countries’, in J. E. Llano-Señarís and C. Campillo-Artero (eds), Health Technology Assessment and Health Policy Today: A Multifaceted View of their Unstable Crossroads, e-book: Springer International Publishing, 109–129.Google Scholar
Löblová, O. (2016), ‘Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe’, Health Economics, Policy and Law, 11(3): 253–273.Google Scholar
Meneu, R. (2015), ‘The Wisdom Tooth of Health Technology Assessment’, in J. E. Llano-Señarís and C. Campillo-Artero (eds), Health Technology Assessment and Health Policy Today: A Multifaceted View of their Unstable Crossroads, e-book: Springer International Publishing, 37–50.Google Scholar
National Institute for Health and Care Excellence (NICE) (2009), ‘Guide to the single technology appraisal process’.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014), ‘Guide to the processes of technology appraisal’.Google Scholar
National Institute for Health and Care Excellence (NICE) (2017), ‘NICE technology appraisal guidance’, https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance [19 January 2017].Google Scholar
National Institute for Health and Care Excellence (NICE) (n.d.), ‘Agreement between the Association of the British Pharmaceutical Industry (ABPI) and the National Institute for Health and Clinical Excellence (NICE) on guidelines for the release of company data into the public domain during a health technology appraisal’.Google Scholar
Nizankowski, R. and Wilk, N. (2009), ‘From idealistic rookies to a regional leader: the history of Health Technology Assessment in Poland’, International Journal of Technology Assessment in Health Care, 25(Suppl. S1): 156–162.Google Scholar
Ordinance on Minimum Requirements (2012), ‘Ordinance of 2nd April 2012 on minimum requirements that have to be met analyses included in applications for reimbursement and setting official retail price and [applications for] increasing the official retail price of medicines, foodstuffs of special designation, medical devices that do not have an equivalent reimbursement in a given indication. (Rozporządzenie Ministra Zdrowia z dnia 2 kwietnia 2012 r. w sprawie minimalnych wymagań, jakie muszą spełniać analizy uwzględnione we wnioskach o objęcie refundacją i ustalenie urzędowej ceny zbytu oraz o podwyższenie urzędowej ceny zbytu leku, środka spożywczego specjalnego przeznaczenia żywieniowego, wyrobu medycznego, które nie mają odpowiednika refundowanego w danym wskazaniu)’.Google Scholar
Ozierański, P. and King, L. (2016), ‘The persistence of cliques in the post-communist state. The case of deniability in drug reimbursement policy in Poland’, The British Journal of Sociology, 67(2): 216–241.Google Scholar
Ozierański, P. and King, L. (2017), ‘Governing drug reimbursement policy in Poland: The role of the state, civil society, and the private sector’, Theory and Society, e-pub ahead of print, https://doi.org/10.1007/s11186-017-9300-8.Google Scholar
Ozierański, P., McKee, M. and King, L. (2012a), ‘The politics of Health Technology Assessment in Poland’, Health Policy, 108(2–3): 178–193.Google Scholar
Ozierański, P., McKee, M. and King, L. (2012b), ‘Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?’, Health Economics, Policy and Law, 7(2): 175–195.Google Scholar
Panteli, D., Eckhardt, H., Nolting, A., Busse, R. and Kulig, M. (2015), ‘From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries’, Health Research Policy and Systems, 13(1): 39.Google Scholar
Plisko, R. (n.d.), ‘Ograniczenia QALY w ocenie technologii stosowanych w stanach terminalnych’. HTA Consulting.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2007), ‘Wytyczne przeprowadzania Oceny Technologii Medycznych (HTA)’. Kraków-Warszawa.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2009), ‘Guidelines for conducting Health Technology Assessment (HTA), version 2.1’. Warsaw.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2012), ‘Komunikat w sprawie tajemnic ustawowo chronionych zawartych w Analizach Wnioskodawcy’. Warszawa.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2014), ‘Komunikat Dotyczący Zakreślania Informacji Stanowiących Tajemnicę Przedsiębiorstwa W Dokumentach Publikowanych W Biuletynie Informacji Publicznej Agencji’. Warszawa.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2015), ‘Zarządzenia Nr 28/2015 Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji’. Warszawa.Google Scholar
Polish Agency for Health Technology Assessment (AHTAPol) (2016), ‘Wytyczne oceny technologii medycznych (HTA, ang. Health Technology Assessment), wersja 3.0’. Warszawa.Google Scholar
Pollitt, C., Bathgate, K., Caulfield, J., Smullen, A. and Talbot, C. (2001), ‘Agency fever? Analysis of an international policy fashion’, Journal of Comparative Policy Analysis, 3(3): 271–290.Google Scholar
The Reimbursement Act (2011), ‘Act of 12th May 2011 on the reimbursement of medicines, foodstufs of special designation and medical products (Ustawa z dnia 12 maja 2011 r. o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych)’.Google Scholar
Sandman, L. and Gustavsson, E. (2016), ‘Beyond the black box approach to ethics!: comment on “expanded HTA: enhancing fairness and legitimacy”’, International Journal of Health Policy and Management, 5(6): 393–394.Google Scholar
Sorenson, C., Drummond, M. and Kanavos, P. (2008), Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union, Volume 11, Europe: WHO Regional Office.Google Scholar
Thatcher, M. (2002), ‘Regulation after delegation: independent regulatory agencies in Europe’, Journal of European Public Policy, 9(6): 954–972.Google Scholar
Velasco Garrido, M., Zentner, A. and Busse, R. (2008), ‘Health Systems, Health Policy and Health Technology Assessment’, in M. V. Garrido, F. B. Kristensen, C. P. Nielsen and R. Busse (eds), Health Teechnology Assessment and Health Ppolicy-Making in Europe. Current Status, Challenges and Potential, e-book: EUnetHTA and European Observatory of Health Systems and Policies, 53–78.Google Scholar